Stay updated on Interchangeability Study of ABP 654 in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Interchangeability Study of ABP 654 in Psoriasis Clinical Trial page.

Latest updates to the Interchangeability Study of ABP 654 in Psoriasis Clinical Trial page
- CheckyesterdayChange DetectedThe record now presents details and results for the completed Phase 3 study of switching between ustekinumab and ABP 654 for plaque psoriasis, along with eligibility criteria, study locations, and related documents.SummaryDifference97%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedA site-wide NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears, and the site revision changes from v3.7.1 to v3.7.2. The study page still displays a 403 Forbidden error.SummaryDifference1%

- Check36 days agoChange DetectedThe ClinicalTrials.gov error page footer now displays site revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study content, with a minimal header and navigation indicating an access restriction. The expected study details and related materials appear unavailable.SummaryDifference19%

- Check71 days agoChange DetectedThe page revision label was updated from v3.6.5 to v3.6.6, indicating a newer document version. This appears to be a metadata revision without changes to study content.SummaryDifference0.0%

- Check92 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5. This represents a small internal update rather than a user-facing content change.SummaryDifference0.0%

Stay in the know with updates to Interchangeability Study of ABP 654 in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Interchangeability Study of ABP 654 in Psoriasis Clinical Trial page.